Suppr超能文献

恶性潜能不确定的甲状腺肿瘤:29例的形态学和免疫组织化学分析

Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.

作者信息

Nechifor-Boila Adela, Borda Angela, Sassolas Geneviève, Hafdi-Nejjari Zakia, Cătană Ramona, Borson-Chazot Françoise, Berger Nicole, Decaussin-Petrucci Myriam

机构信息

Department of Histology, University of Medicine and Pharmacy, 38 Gheorghe Marinescu Str, Tîrgu-Mureş 540000, Romania.

Department of Histology, University of Medicine and Pharmacy, 38 Gheorghe Marinescu Str, Tîrgu-Mureş 540000, Romania.

出版信息

Pathol Res Pract. 2015 Apr;211(4):320-5. doi: 10.1016/j.prp.2014.12.005. Epub 2014 Dec 22.

Abstract

INTRODUCTION

Thyroid tumors of uncertain malignant potential (TT-UMP) include follicular and well-differentiated tumors of UMP (FT-UMP/WDT-UMP), as it refers to the presence of questionable capsular/vascular invasion or incompletely developed papillary thyroid carcinoma (PTC)-type nuclear changes. However, these tumors are difficult to diagnose in most cases. We aimed to investigate whether immunohistochemistry (HBME-1, cytokeratin-19, galectin-3, CD56 and p63) provides additional information concerning such lesions.

MATERIALS AND METHODS

We performed an immunohistochemical analysis on 29 TT-UMP cases (22 WDTs-UMP and 7 FTs-UMP) selected from the Rhone Alpes thyroid cancer registry and Departement of Pathology, Tîrgu-Mureş Emergency County Hospital database. The clinicopathological and follow-up data were obtained.

RESULTS

In the WDT-UMP group, HBME-1 was positive in 9/22 (40.9%) cases. CD56, a marker whose expression is reduced or absent in thyroid carcinoma, showed a "malignant" profile (no expression) in 13/22 (59.1%) cases. 7/22 (31.9%) cases were both HBME-1+ and CD56-. One case showed the co-expression of HBME-1, CD56, galectin-3 and cytokeratin-19. In the FT-UMP group, two cases were positive for HBME-1, other two for both galectin-3 and CK19 and only one case revealed a "malignant" CD56 profile. The follow-up data showed no distant metastases or persistent disease.

CONCLUSION

Our study demonstrated very heterogeneous immunohistochemical profiles for TTs-UMP, further supporting the borderline nature of these lesions. WDTs-UMP revealed a certain tendency toward a PTC profile, suggesting a possible pathogeneticlink between these two entities. However, immunohistochemistry is still to be regarded more as a supporting diagnostic tool, while morphological criteria should always prime in the diagnostic decision.

摘要

引言

具有不确定恶性潜能的甲状腺肿瘤(TT-UMP)包括具有不确定恶性潜能的滤泡性肿瘤和高分化肿瘤(FT-UMP/WDT-UMP),这是指存在可疑的包膜/血管侵犯或不完全发育的甲状腺乳头状癌(PTC)型核变化。然而,在大多数情况下,这些肿瘤难以诊断。我们旨在研究免疫组织化学(HBME-1、细胞角蛋白-19、半乳糖凝集素-3、CD56和p63)是否能为此类病变提供更多信息。

材料与方法

我们对从罗纳-阿尔卑斯甲状腺癌登记处和特尔古穆列什紧急县医院病理科数据库中选取的29例TT-UMP病例(22例WDTs-UMP和7例FTs-UMP)进行了免疫组织化学分析。获取了临床病理和随访数据。

结果

在WDT-UMP组中,HBME-1在9/22(40.9%)的病例中呈阳性。CD56是一种在甲状腺癌中表达降低或缺失的标志物,在13/22(59.1%)的病例中呈现“恶性”特征(无表达)。7/22(31.9%)的病例HBME-1阳性且CD56阴性。1例病例显示HBME-1、CD56、半乳糖凝集素-3和细胞角蛋白-19共表达。在FT-UMP组中,2例病例HBME-1阳性,另外2例半乳糖凝集素-3和CK19均阳性,只有1例病例呈现“恶性”CD56特征。随访数据显示无远处转移或持续性疾病。

结论

我们的研究表明TTs-UMP的免疫组织化学特征非常异质性,进一步支持了这些病变的临界性质。WDTs-UMP显示出一定的向PTC特征发展的趋势,提示这两种实体之间可能存在致病联系。然而,免疫组织化学仍应更多地被视为一种辅助诊断工具,而形态学标准在诊断决策中应始终占主导地位。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验